Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine-Reference-Cited by-同舟云学术

Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine

Published:2020-04-01 Issue:4 Volume:30 Page:476-478
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Klubo-Gwiezdzinska Joanna¹,Chen Xiaoyuan²

Affiliation:

1. Thyroid Tumors and Functional Thyroid Disorders Section, Metabolic Disease Branch, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

2. Molecular Imaging and Nanomedicine Laboratory, National Institutes of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2020.0169

Reference15 articles.

1. Every step of the way: integrins in cancer progression and metastasis

2. End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma

3. Differential Pattern of Integrin Receptor Expression in Differentiated and Anaplastic Thyroid Cancer Cell Lines

4. The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer;The Journal of Clinical Endocrinology & Metabolism;2024-08-08

2. Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer;Cancers;2024-04-02

3. Evaluation of integrin αvβ3-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2);Cancer Imaging;2022-12-19

4. Radiometal-theranostics: the first 20 years*;Journal of Radioanalytical and Nuclear Chemistry;2022-11-24

5. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead;Frontiers in Endocrinology;2022-07-12